Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;196(1):143-152.
doi: 10.1007/s10549-022-06688-z. Epub 2022 Aug 25.

Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers

Maryam Nemati Shafaee  1   2 , Kristina Goutsouliak  3 , Heather Lin  4 , Therese B Bevers  4 , Angelica Gutierrez-Barrera  4 , Melissa Bondy  5 , Banu Arun  4
Affiliations

Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers

Maryam Nemati Shafaee et al. Breast Cancer Res Treat. 2022 Nov.

Abstract

Background: Deleterious BRCA mutations confer a significant lifetime risk of breast cancer (BC) as well as contralateral BC (CBC) in patients who do not undergo prophylactic mastectomy. Prior reports have suggested that tamoxifen reduces the risk of CBC in BRCA mutation carriers. Whether aromatase inhibitors (AI) have the same effect is unknown.

Methods: This is a retrospective review of patients diagnosed with non-metastatic ER+ BC between 2004 and 2014 with known BRCA mutation status. Patients were followed from primary diagnosis until CBC diagnosis or death. Median follow-up was 11.5 years. Risk of CBC was evaluated as time to event.

Results: 935 subjects were included in this analysis, with 53 BRCA1 mutation carriers, and 94 BRCA2 mutation carriers. Median age at diagnosis was 42.7 years. Seventy-two percent (676) received tamoxifen and 43% (405) received AI. A total of 66 CBCs occurred, of which 10% (15/147) occurred in BRCA mutation carriers vs 6.5% (51/788) in BRCA wild type. Multivariate analyses indicated that BRCA status and AI use were significantly associated with CBC risk. AI use resulted in a significant reduction in risk of CBC (HR 0.44, p = 0.004) regardless of the BRCA mutation status. Tamoxifen use was not associated with reduced risk of CBC.

Conclusions: This is the first report showing that AIs reduce the risk of CBC in BRCA mutation carriers. The potential role of AIs as chemoprevention should be validated in larger independent cohorts.

Keywords: Aromatase inhibitors; BRCA mutation; BRCA1/2; Breast cancer; Chemoprevention; High risk; Tamoxifen.

PubMed Disclaimer

References

    1. Ford D et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62(3):676–89 - DOI
    1. Metcalfe KA, Narod SA (2007) Breast cancer prevention in women with a BRCA1 or BRCA2 mutation. Open Med 1(3):e184–e190 - PubMed - PMC
    1. Cortesi L, Rugo HS, Jackisch C (2021) An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol 16(3):255–282 - DOI
    1. Kotsopoulos J (2018) Mutations and breast cancer prevention. Cancers (Basel) 10(12):524 - DOI
    1. Metcalfe K et al (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22(12):2328–2335 - DOI